Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
AssigneeScidose LLC
InventorNageswara R. Palepu
Life of this patent
Estimating the term…
Abstract
Formulations comprising docetaxel or a salt thereof in combination with α-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.
Claims20
A solid docetaxel formulation comprising a first component comprising docetaxel or a pharmaceutically acceptable salt thereof and a second component comprising a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, where the second component is present and in an amount of greater than 0.025 to less than 2.5 parts by weight based on α-lipoic acid or dihydrolipoic acid respectively per 1 part of said first component based on free docetaxel.
A liquid solution docetaxel formulation comprising
- a first component comprising docetaxel or a pharmaceutically acceptable salt thereof in an amount less than 15 mg (based on free docetaxel)/ml of said solution;
- a second component comprising a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, and in an amount of greater than 0.025 to less than 2.5 parts by weight based on α-lipoic acid or dihydrolipoic acid respectively per part of said first component based on free docetaxel;
- and
- a solvent capable of dissolving said docetaxel at a concentration of at least up to 15 mg/ml of solution.
A liquid solution docetaxel formulation comprising
- a first component comprising docetaxel or a pharmaceutically acceptable salt thereof in an amount in excess of 10 mg/ml of said solution;
- a second component comprising a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, and in an amount of greater than 0.025 to less than 2.5 parts by weight based on α-lipoic acid or dihydrolipoic acid respectively per part of said first component based on free docetaxel;
- and
- a solvent for said docetaxel capable of dissolving said docetaxel in an amount in excess of 10 mg/ml of solution.
An infusion solution comprising
- a first component comprising docetaxel or a pharmaceutically acceptable salt thereof in an infusion suitable concentration;
- a second component comprising a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof,
- a solvent for said first component;
- said solvent capable of dissolving said first component;
- and an infusion liquid diluent in an amount such that said first component is present in an infusion acceptable concentration and said second component is present in an amount of from more than 0.025 parts to less than 2.5 parts by weight of α-lipoic acid (or a pharmaceutically acceptable salt thereof based upon free α-lipoic acid) or dihydrolipoic acid (or a pharmaceutically acceptable salt thereof based upon free dihydrolipoic acid) per part by weight of said first component based on free docetaxel.
A method of preparing an infusion solution containing docetaxel or a pharmaceutically acceptable salt thereof, said infusion solution comprising
- (a) docetaxel or a pharmaceutically acceptable salt thereof,
- (b) a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof;
- and
- (c) an infusion suitable infusion fluid;
- comprising firstly combining said member with at least one of
- (a) a solid formulation of docetaxel or pharmaceutically acceptable salt thereof;
- (b) a liquid solution of docetaxel or a pharmaceutically acceptable salt thereof;
- to result in a combination product and
- further secondly combining said combination product with said infusion fluid;
- said firstly combining being in an amount for said first member to be present in at least said infusion solution in an amount of from more than 0.025 parts to less than 2.5 parts by weight based on free α-lipoic acid or free dihydrolipoic acid respectively per 1 part by weight of said docetaxel or pharmaceutically acceptable salt thereof based on free docetaxel.
A method of preparing a concentrate solution containing docetaxel or a pharmaceutically acceptable salt thereof, said concentrate solution comprising
- (a) docetaxel or a pharmaceutically acceptable salt thereof,
- (b) a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, and
- (c) a solvent for said docetaxel or pharmaceutically acceptable salt thereof comprising combining said member with at least one of
- (a) a solid formulation of docetaxel or pharmaceutically acceptable salt thereof;
- and
- (b) a liquid solution of docetaxel or a pharmaceutically acceptable salt thereof;
- in an amount for said member to be present in at least said concentrate solution in an amount of from more than 0.025 parts to less than 2.5 parts by weight based on free α-lipoic acid or free dihydrolipoic acid respectively per 1 part by weight of said docetaxel or pharmaceutically acceptable salt thereof based on free docetaxel.
A method of treating a docetaxel responsive condition in a patient in need thereof via an infusion comprising administering to said patient a pharmaceutically effective amount for said docetaxel responsive condition of an infusion containing docetaxel or a pharmaceutically acceptable salt thereof and a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, in an amount of from more than 0.025 parts to less than 2.5 parts by weight based on free α-lipoic acid or free dihydrolipoic acid respectively per 1 part by weight of said docetaxel or pharmaceutically acceptable salt thereof based on free docetaxel.
A method of extending the stability of a liquid concentrate formulation containing docetaxel or a pharmaceutically acceptable salt thereof comprising incorporating into said concentrate formulation a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, in an amount of from more than 0.025 parts to less than 2.5 parts by weight based on free α-lipoic acid or free dihydrolipoic acid respectively per 1 part by weight of said docetaxel or pharmaceutically acceptable salt thereof based on free docetaxel.
A method of extending the time period in which a docetaxel liquid formulation is to be used, measured between
- (a) dilution of a more highly concentrated formulation to concentrations of less than 15 mg docetaxel/ml of solution until
- (b) completion of administration of an infusion made therefrom;
- said extending being measured between (a) a period of not more than 4 hours to (b) a period greater than 4 hours;
- comprising including a member selected from the group consisting of α-lipoic acid or a pharmaceutically acceptable salt thereof, dihydrolipoic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, in an amount of from more than 0.025 parts to less than 2.5 parts by weight based on free α-lipoic acid or free dihydrolipoic acid respectively per 1 part by weight of said docetaxel or pharmaceutically acceptable salt thereof based on free docetaxel into said formulation and inclusion of said member is at least one of (a) a point in time when said more highly concentrated formulation is diluted to concentrations of less than about 15 mg/ml of docetaxel or pharmaceutically acceptable salt thereof based on free docetaxel, or (b) inclusion in said more highly concentrated formulation prior to said dilution, or (c) inclusion as a blend with said solid docetaxel or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.